Recursion Pharmaceuticals (RXRX) EBITDA (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly EBITDA came in at -$128.5 million in Q1 2026, up 32.85% YoY from -$96.7 million in Q1 2025, and down 18.62% on a QoQ basis from -$108.3 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) EBITDA (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of EBITDA data on file, last reported at -$128.5 million in Q1 2026.
- Quarterly EBITDA rose 32.85% year-over-year to -$128.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$585.3 million (down 1.96% YoY) and the FY2025 annual result came in at -$648.1 million, down 35.31% from the prior year.
- EBITDA fell to -$128.5 million in Q1 2026, from -$108.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$56.0 million in Q1 2022 to a low of -$191.4 million in Q1 2025.
- A 5-year average of -$108.9 million and a median of -$98.9 million in 2023 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 41.05% in 2025, down 98.64% in 2025.
- Tracing RXRX's EBITDA over 5 years: stood at -$61.0 million in 2022, then tumbled by 62.23% to -$98.9 million in 2023, then tumbled by 85.76% to -$183.8 million in 2024, then jumped by 41.05% to -$108.3 million in 2025, then dropped by 18.62% to -$128.5 million in 2026.
- The last three EBITDA figures came in at -$128.5 million (Q1 2026), -$108.3 million (Q4 2025), and -$172.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -134.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -134.97 Mn |
| Mar 31, 2026 | -128.51 Mn |
| Dec 31, 2025 | -108.33 Mn |
| Sep 30, 2025 | -172.20 Mn |
| Jun 30, 2025 | -176.23 Mn |
| Mar 31, 2025 | -191.37 Mn |
| Dec 31, 2024 | -183.77 Mn |
| Sep 30, 2024 | -98.35 Mn |
| Jun 30, 2024 | -100.54 Mn |
| Mar 31, 2024 | -96.34 Mn |
| Dec 31, 2023 | -98.93 Mn |
| Sep 30, 2023 | -99.55 Mn |
| Jun 30, 2023 | -81.72 Mn |
| Mar 31, 2023 | -69.87 Mn |
| Dec 31, 2022 | -60.98 Mn |
| Sep 30, 2022 | -62.57 Mn |
| Jun 30, 2022 | -66.19 Mn |
| Mar 31, 2022 | -55.98 Mn |
| Dec 31, 2021 | -64.96 Mn |
| Sep 30, 2021 | -46.40 Mn |